A citation-based method for searching scientific literature

Gina López-Cantillo, Claudia Urueña, Bernardo Armando Camacho, Cesar Ramírez-Segura. Front Immunol 2022
Times Cited: 5







List of co-cited articles
11 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Sabine Heitzeneder, Kristopher R Bosse, Zhongyu Zhu, Doncho Zhelev, Robbie G Majzner, Molly T Radosevich, Shaurya Dhingra, Elena Sotillo, Samantha Buongervino, Guillem Pascual-Pasto,[...]. Cancer Cell 2022
19
40

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
40

CAR-NK cells for cancer immunotherapy: from bench to bedside.
Leisheng Zhang, Yuan Meng, Xiaoming Feng, Zhongchao Han. Biomark Res 2022
10
40

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Dana Stenger, Tanja A Stief, Theresa Kaeuferle, Semjon Willier, Felicitas Rataj, Kilian Schober, Binje Vick, Ramin Lotfi, Beate Wagner, Thomas G P Grünewald,[...]. Blood 2020
58
40

PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
Christopher Ronald Funk, Shuhua Wang, Kevin Z Chen, Alexandra Waller, Aditi Sharma, Claudia L Edgar, Vikas A Gupta, Shanmuganathan Chandrakasan, Jaquelyn T Zoine, Andrew Fedanov,[...]. Blood 2022
12
40

Advances in Universal CAR-T Cell Therapy.
Haolong Lin, Jiali Cheng, Wei Mu, Jianfeng Zhou, Li Zhu. Front Immunol 2021
18
40

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
Gils Roex, Marijke Timmers, Kristien Wouters, Diana Campillo-Davo, Donovan Flumens, Wilfried Schroyens, Yiwei Chu, Zwi N Berneman, Eva Lion, Feifei Luo,[...]. J Hematol Oncol 2020
45
40

'Off-the-shelf' allogeneic CAR T cells: development and challenges.
S Depil, P Duchateau, S A Grupp, G Mufti, L Poirot. Nat Rev Drug Discov 2020
334
40

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
Justin Eyquem, Jorge Mansilla-Soto, Theodoros Giavridis, Sjoukje J C van der Stegen, Mohamad Hamieh, Kristen M Cunanan, Ashlesha Odak, Mithat Gönen, Michel Sadelain. Nature 2017
888
40

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.
D Sommermeyer, M Hudecek, P L Kosasih, T Gogishvili, D G Maloney, C J Turtle, S R Riddell. Leukemia 2016
485
40

Universal CARs, universal T cells, and universal CAR T cells.
Juanjuan Zhao, Quande Lin, Yongping Song, Delong Liu. J Hematol Oncol 2018
133
40

Natural killer cells in antitumour adoptive cell immunotherapy.
Tamara J Laskowski, Alexander Biederstädt, Katayoun Rezvani. Nat Rev Cancer 2022
12
20

Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.
J G Villablanca, A A Khan, V I Avramis, R C Seeger, K K Matthay, N K Ramsay, C P Reynolds. J Clin Oncol 1995
128
20

Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions.
Jessica Matta, Myriam Baratin, Laurent Chiche, Jean-Marie Forel, Céline Cognet, Guillemette Thomas, Catherine Farnarier, Christelle Piperoglou, Laurent Papazian, Damien Chaussabel,[...]. Blood 2013
102
20

Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7-H3 surface molecule.
A Gregorio, M V Corrias, R Castriconi, A Dondero, M Mosconi, C Gambini, A Moretta, L Moretta, C Bottino. Histopathology 2008
62
20

Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages.
Francesca Bellora, Alessandra Dondero, Maria Valeria Corrias, Beatrice Casu, Stefano Regis, Fabio Caliendo, Alessandro Moretta, Mario Cazzola, Chiara Elena, Luciana Vinti,[...]. J Immunol 2017
31
20

KIR and KIR ligand polymorphism: a new area for clinical applications?
M Falco, L Moretta, A Moretta, C Bottino. Tissue Antigens 2013
45
20

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO.
Nikolai Siebert, Maxi Zumpe, Madlen Jüttner, Sascha Troschke-Meurer, Holger N Lode. Oncoimmunology 2017
38
20

An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism.
Jerod L Ptacin, Carolina E Caffaro, Lina Ma, Kristine M San Jose Gall, Hans R Aerni, Nicole V Acuff, Rob W Herman, Yelena Pavlova, Michael J Pena, David B Chen,[...]. Nat Commun 2021
25
20

Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC.
Christina Battke, Romana Ruiss, Ulrich Welsch, Pauline Wimberger, Stephan Lang, Simon Jochum, Reinhard Zeidler. Cancer Immunol Immunother 2011
106
20

Safety and immune cell kinetics after donor natural killer cell infusion following haploidentical stem cell transplantation in children with recurrent neuroblastoma.
Young Bae Choi, Meong Hi Son, Hee Won Cho, Youngeun Ma, Ji Won Lee, Eun-Suk Kang, Keon Hee Yoo, Jung Hyun Her, Okjae Lim, Miyoung Jung,[...]. PLoS One 2019
6
20


Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155.
Baofu Zhang, Weina Zhao, Huizhong Li, Yuanyuan Chen, Hui Tian, Liantao Li, Longzhen Zhang, Chao Gao, Junnian Zheng. Cancer Immunol Immunother 2016
40
20

IL-15 trans-presentation promotes human NK cell development and differentiation in vivo.
Nicholas D Huntington, Nicolas Legrand, Nuno L Alves, Barbara Jaron, Kees Weijer, Ariane Plet, Erwan Corcuff, Erwan Mortier, Yannick Jacques, Hergen Spits,[...]. J Exp Med 2009
388
20

Haploidentical Stem Cell Transplantation for Refractory/Relapsed Neuroblastoma.
Toni Illhardt, Jacek Toporski, Tobias Feuchtinger, Dominik Turkiewicz, Heiko-Manuel Teltschik, Martin Ebinger, Carl-Philipp Schwarze, Ursula Holzer, Holger N Lode, Michael H Albert,[...]. Biol Blood Marrow Transplant 2018
27
20

High-Risk and Relapsed Neuroblastoma: Toward More Cures and Better Outcomes.
Steven G DuBois, Margaret E Macy, Tara O Henderson. Am Soc Clin Oncol Educ Book 2022
4
25

Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma.
Ombretta Melaiu, Marco Chierici, Valeria Lucarini, Giuseppe Jurman, Libenzio Adrian Conti, Rita De Vito, Renata Boldrini, Loredana Cifaldi, Aurora Castellano, Cesare Furlanello,[...]. Nat Commun 2020
54
20

Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis.
Roberta Castriconi, Alessandra Dondero, Raffaella Augugliaro, Claudia Cantoni, Barbara Carnemolla, Angela Rita Sementa, Francesca Negri, Romana Conte, Maria Valeria Corrias, Lorenzo Moretta,[...]. Proc Natl Acad Sci U S A 2004
204
20

Donor NK Cells and IL-15 promoted engraftment in nonmyeloablative allogeneic bone marrow transplantation.
Bo Hu, Guangming Bao, Yinsheng Zhang, Dandan Lin, Yan Wu, Depei Wu, Haiyan Liu. J Immunol 2012
17
20

Neuroblastoma Heterogeneity, Plasticity, and Emerging Therapies.
Kristina Ihrmark Lundberg, Diana Treis, John Inge Johnsen. Curr Oncol Rep 2022
7
20


CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Robbie G Majzner, Johanna L Theruvath, Anandani Nellan, Sabine Heitzeneder, Yongzhi Cui, Christopher W Mount, Skyler P Rietberg, Miles H Linde, Peng Xu, Christopher Rota,[...]. Clin Cancer Res 2019
244
20

Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development.
Patrick Ming-Kuen Tang, Shuang Zhou, Xiao-Ming Meng, Qing-Ming Wang, Chun-Jie Li, Guang-Yu Lian, Xiao-Ru Huang, Yong-Jiang Tang, Xin-Yuan Guan, Bryan Ping-Yen Yan,[...]. Nat Commun 2017
105
20


NKG2D ligands in tumor immunity.
N Nausch, A Cerwenka. Oncogene 2008
292
20

GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Matteo Caforio, Cristina Sorino, Ignazio Caruana, Gerrit Weber, Antonio Camera, Loredana Cifaldi, Biagio De Angelis, Francesca Del Bufalo, Alessia Vitale, Bianca Maria Goffredo,[...]. J Immunother Cancer 2021
6
20

Oral cancer cell‑derived exosomes modulate natural killer cell activity by regulating the receptors on these cells.
Xueqin Zhu, Xing Qin, Xiaoning Wang, Yingnan Wang, Wei Cao, Jianjun Zhang, Wantao Chen. Int J Mol Med 2020
14
20

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.
Daniela Pende, Stefania Marcenaro, Michela Falco, Stefania Martini, Maria Ester Bernardo, Daniela Montagna, Elisa Romeo, Céline Cognet, Miryam Martinetti, Rita Maccario,[...]. Blood 2009
297
20

Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more.
Laura Chiossone, Margaux Vienne, Yann M Kerdiles, Eric Vivier. Semin Immunol 2017
79
20

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
Loredana Ruggeri, Marusca Capanni, Elena Urbani, Katia Perruccio, Warren D Shlomchik, Antonella Tosti, Sabrina Posati, Daniela Rogaia, Francesco Frassoni, Franco Aversa,[...]. Science 2002
20

Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients.
Dominique Valteau-Couanet, Christophe Leboulaire, Kim Maincent, Muriel Tournier, Olivier Hartmann, Jean Bénard, Françoise Beaujean, Catherine Boccaccio, Laurence Zitvogel, Eric Angevin. Blood 2002
47
20

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes.
Ignazio Caruana, Barbara Savoldo, Valentina Hoyos, Gerrit Weber, Hao Liu, Eugene S Kim, Michael M Ittmann, Dario Marchetti, Gianpietro Dotti. Nat Med 2015
399
20

Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals.
Jaewon Lee, Tianxiang Zhang, Ilwoong Hwang, Ahrom Kim, Larissa Nitschke, MinJae Kim, Jeannine M Scott, Yosuke Kamimura, Lewis L Lanier, Sungjin Kim. Immunity 2015
346
20


Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Isaac Yaniv, Genevieve Laureys, Penelope Brock, Jean Marie Michon, Cormac Owens,[...]. Lancet Oncol 2018
162
20


Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.
Brian H Kushner, Irina Ostrovnaya, Irene Y Cheung, Deborah Kuk, Shakeel Modak, Kim Kramer, Stephen S Roberts, Ellen M Basu, Karima Yataghene, Nai-Kong V Cheung. Oncotarget 2016
37
20

Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia.
Chang-Sook Hong, Priyanka Sharma, Saigopalakrishna S Yerneni, Patricia Simms, Edwin K Jackson, Theresa L Whiteside, Michael Boyiadzis. Sci Rep 2017
122
20

Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation.
Onder Alpdogan, Jeffrey M Eng, Stephanie J Muriglan, Lucy M Willis, Vanessa M Hubbard, Kartono H Tjoe, Theis H Terwey, Adam Kochman, Marcel R M van den Brink. Blood 2005
112
20

Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors.
Aicha E Quamine, Mallery R Olsen, Monica M Cho, Christian M Capitini. Cancers (Basel) 2021
5
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.